Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.46
EDAP's Cash to Debt is ranked higher than
74% of the 513 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. EDAP: 3.46 )
EDAP' s 10-Year Cash to Debt Range
Min: 0.37   Max: 12.46
Current: 3.46

0.37
12.46
Equity to Asset 0.47
EDAP's Equity to Asset is ranked higher than
56% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. EDAP: 0.47 )
EDAP' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.73
Current: 0.47

0.25
0.73
F-Score: 5
Z-Score: 1.75
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6.35
EDAP's Operating margin (%) is ranked higher than
63% of the 488 Companies
in the Global Medical Devices industry.

( Industry Median: 4.77 vs. EDAP: -6.35 )
EDAP' s 10-Year Operating margin (%) Range
Min: -43.96   Max: -2.5
Current: -6.35

-43.96
-2.5
Net-margin (%) -2.27
EDAP's Net-margin (%) is ranked higher than
66% of the 488 Companies
in the Global Medical Devices industry.

( Industry Median: 3.24 vs. EDAP: -2.27 )
EDAP' s 10-Year Net-margin (%) Range
Min: -53.64   Max: 42.97
Current: -2.27

-53.64
42.97
ROE (%) -5.76
EDAP's ROE (%) is ranked higher than
65% of the 479 Companies
in the Global Medical Devices industry.

( Industry Median: 4.18 vs. EDAP: -5.76 )
EDAP' s 10-Year ROE (%) Range
Min: -111.74   Max: 44.99
Current: -5.76

-111.74
44.99
ROA (%) -3.32
EDAP's ROA (%) is ranked higher than
66% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 1.45 vs. EDAP: -3.32 )
EDAP' s 10-Year ROA (%) Range
Min: -31.62   Max: 25.67
Current: -3.32

-31.62
25.67
ROC (Joel Greenblatt) (%) -22.49
EDAP's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 512 Companies
in the Global Medical Devices industry.

( Industry Median: 5.87 vs. EDAP: -22.49 )
EDAP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -86.63   Max: -9.97
Current: -22.49

-86.63
-9.97
Revenue Growth (3Y)(%) -14.00
EDAP's Revenue Growth (3Y)(%) is ranked higher than
55% of the 348 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. EDAP: -14.00 )
EDAP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -17.3   Max: 11
Current: -14

-17.3
11
EBITDA Growth (3Y)(%) -43.90
EDAP's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. EDAP: -43.90 )
EDAP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -66.5   Max: 157.1
Current: -43.9

-66.5
157.1
EPS Growth (3Y)(%) -35.50
EDAP's EPS Growth (3Y)(%) is ranked higher than
57% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. EDAP: -35.50 )
EDAP' s 10-Year EPS Growth (3Y)(%) Range
Min: -36.7   Max: 241.1
Current: -35.5

-36.7
241.1
» EDAP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

EDAP Guru Trades in Q1 2014

Robert Bruce 1,565,494 sh (unchged)
» More
Q2 2014

EDAP Guru Trades in Q2 2014

Robert Bruce 1,565,494 sh (unchged)
» More
Q3 2014

EDAP Guru Trades in Q3 2014

Robert Bruce 1,565,494 sh (unchged)
» More
Q4 2014

EDAP Guru Trades in Q4 2014

Robert Bruce 1,565,494 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EDAP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 80.65
EDAP's Forward P/E is ranked higher than
74% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EDAP: 80.65 )
N/A
P/B 4.12
EDAP's P/B is ranked higher than
64% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. EDAP: 4.12 )
EDAP' s 10-Year P/B Range
Min: 0.5   Max: 18.2
Current: 4.12

0.5
18.2
P/S 2.06
EDAP's P/S is ranked higher than
72% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 3.99 vs. EDAP: 2.06 )
EDAP' s 10-Year P/S Range
Min: 0.37   Max: 6
Current: 2.06

0.37
6
EV-to-EBIT -29.36
EDAP's EV-to-EBIT is ranked higher than
57% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EDAP: -29.36 )
EDAP' s 10-Year EV-to-EBIT Range
Min: -8809.6   Max: 87.7
Current: -29.36

-8809.6
87.7
Current Ratio 2.19
EDAP's Current Ratio is ranked higher than
66% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. EDAP: 2.19 )
EDAP' s 10-Year Current Ratio Range
Min: 1.27   Max: 3.92
Current: 2.19

1.27
3.92
Quick Ratio 1.70
EDAP's Quick Ratio is ranked higher than
67% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 1.93 vs. EDAP: 1.70 )
EDAP' s 10-Year Quick Ratio Range
Min: 1.07   Max: 3.38
Current: 1.7

1.07
3.38
Days Inventory 73.62
EDAP's Days Inventory is ranked higher than
90% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 180.69 vs. EDAP: 73.62 )
EDAP' s 10-Year Days Inventory Range
Min: 95.66   Max: 298.9
Current: 73.62

95.66
298.9
Days Sales Outstanding 103.86
EDAP's Days Sales Outstanding is ranked higher than
65% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 83.08 vs. EDAP: 103.86 )
EDAP' s 10-Year Days Sales Outstanding Range
Min: 77.32   Max: 249.93
Current: 103.86

77.32
249.93

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 6.43
EDAP's Price/Net Current Asset Value is ranked higher than
77% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EDAP: 6.43 )
EDAP' s 10-Year Price/Net Current Asset Value Range
Min: 0.29   Max: 19.45
Current: 6.43

0.29
19.45
Price/Tangible Book 4.90
EDAP's Price/Tangible Book is ranked higher than
75% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 7.90 vs. EDAP: 4.90 )
EDAP' s 10-Year Price/Tangible Book Range
Min: 0.22   Max: 16.68
Current: 4.9

0.22
16.68
Price/Median PS Value 1.34
EDAP's Price/Median PS Value is ranked higher than
70% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 1.30 vs. EDAP: 1.34 )
EDAP' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 4.74
Current: 1.34

0.32
4.74
Earnings Yield (Greenblatt) -3.40
EDAP's Earnings Yield (Greenblatt) is ranked higher than
59% of the 497 Companies
in the Global Medical Devices industry.

( Industry Median: 1.30 vs. EDAP: -3.40 )
EDAP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 156434.3
Current: -3.4

1.1
156434.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EDA.Germany,
EDAP TMS SA was incorporated on December 3, 1979 as a Societe Anonyme organized under the laws of the Republic of France for 60 years from the date of incorporation. It is a holding Company and is responsible for providing common services to its subsidiaries, including preparation and consolidation of the financial statements for the group, complying with the requirements of various regulatory agencies and maintaining the listing of its publicly held securities. Its activity is organized in two divisions: HIFU and UDS. Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases. It's HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. Its HIFU business is quite seasonal and generally linked to lengthy hospital decision and investment processes. In addition to developing, manufacturing and marketing HIFU devices, the HIFU division also generates revenues from leasing equipment, as well as from the sale of disposables, spare parts and maintenance services. Currently, the only commercial product of the Company utilizing HIFU technology is the Ablatherm, an ultrasound guided HIFU device for the treatment of organ-confined prostate cancer. As of December 31, 2013, the HIFU division's patent portfolio contained 36 patents consisting of 16 in the United States, 18 in the European Union and Japan and 2 in Israel and the rest of the world. They belong to 18 groups of patents covering key technologies related to therapeutic ultrasound principles, systems and associated software. The UDS division's main business is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. In addition to its manufacturing and selling of lithotripters, the UDS division also generates revenues from the leasing of lithotripters, as well as from the sale of disposables, spare parts and maintenance services. The UDS division offers the Sonolith i-move to small and mid-size hospitals, while the Sonolith i-sys is offered to large hospitals that can afford a fully dedicated and integrated lithotripter. Ablatherm-HIFU device competes with all current treatments for localized tumors, which include surgery, brachytherapy, radiotherapy, cryotherapy and hormonotherapy. The Company and its products are regulated in the United States by the FDA under a number of statutes including the Federal Food, Drug and Cosmetic Act.
» More Articles for EDAP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
EDAP TMS SA Financials Apr 08 2015
EDAP Reports Fourth Quarter and Full Year 2014 Results Apr 01 2015
Q4 2014 Edap Tms SA Earnings Release - After Market Close Apr 01 2015
EDAP Announces Sale of First Focal One(R) HIFU Device in North America Mar 31 2015
EDAP to Participate in Major, Multi-Partner Liver Cancer Development Project Mar 26 2015
EDAP to Report Fourth Quarter and Full-Year 2014 Results on April 2, 2015 Mar 17 2015
EDAP Announces Plans to Pursue Direct De Novo 510(k) Petition in Lieu of PMA for Its Ablatherm HIFU Mar 09 2015
EDAP Expands Product Portfolio With New Urological Stone Lasers Feb 26 2015
Friday's Morning Movers: Earnings Start To Trickle In Jan 09 2015
EDAP Reports Continued Strong Growth in Third Quarter 2014 Nov 20 2014
EDAP Receives FDA Guidance on PMA for Ablatherm-HIFU Nov 06 2014
EDAP to Report Third Quarter 2014 Results on November 20, 2014 Nov 04 2014
EDAP Announces Sale of Focal One(R) HIFU Device to Nantes-Atlantis Urology Clinic in France Oct 21 2014
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action against EDAP TMS S.A. and... Sep 29 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A.... Sep 25 2014
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of EDAP TMS S.A. Of Upcoming Deadline Sep 18 2014
Cohen Milstein Sellers & Toll PLLC Announces the Investigation of EDAP TMS S.A. Sep 05 2014
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In... Aug 29 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A.... Aug 29 2014
Investors of EDAP TMS S.A. With Losses of $50,000 or More Are Encouraged to Contact Law Offices of... Aug 27 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK